This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch | The Motley Fool
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

Source: The Motley Fool
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.